J&J Not Seeking To Undercut Incivek, Victrelis On Olysio’s Pricing
Executive Summary
While Olysio will be priced higher than Incivek for the course of therapy, J&J has a broader strategy for use of the second-generation protease inhibitor. Market analysts are skeptical about the drug’s prospects even though it has some clear edges over the first-generation protease inhibitors for hepatitis C.